

## Correction: Prognostic and clinicopathological value of p53 expression in renal cell carcinoma: a meta-analysis

Zhun Wang<sup>1</sup>, Shuanghe Peng<sup>1</sup>, Ning Jiang<sup>1</sup>, Aixiang Wang<sup>1</sup>, Shuguang Liu<sup>1</sup>, Hui Xie<sup>1</sup>, Linpei Guo<sup>1</sup>, Qiliang Cai<sup>1</sup> and Yuanjie Niu<sup>1</sup>

<sup>1</sup> Departments of Urology, Tianjin Institute of Urology, The second Hospital of Tianjin Medical University, Tianjin, 300211, China

**Published:** November 20, 2018

**Copyright:** Wang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**This article has been corrected:** The correct Funding information is given below:

### FUNDING

This meta-analysis has been financially supported by the National Natural Science Foundation of China (No. 81472682 and No. 81572538) and the Science Foundation of Tianjin (No. 16JCZDJC34400).

Original article: Oncotarget. 2017; 8:102361-102370. <https://doi.org/10.18632/oncotarget.21971>